The future healthcare market landscape is quickly changing, and it is necessary to have a partner who can deliver the services you need. Having a comprehensive anatomic pathology strategy can be crucial to ensuring clinical and commercial success of your product.
With access to commercial clinical laboratories and a full in-house global Anatomic Pathology (AP) service
with a foot print in the Americas, Europe, Asia-Pac and China, and a lab operations team who are adept at assay transfer and validation, we have the ability to support your unique study needs. We create tailored solutions for every trial, based on tissue and tumor type, staining requirements, and the need for customized assays. Download our brochure
to learn more about our AP capabilities. Companion Diagnostic experience
– Our scientific experts provide you with an optimal path to co-develop your companion diagnostic with clinical development of the therapeutic, regulatory submission and market launch. Our integrated approach is designed so you optimize time to market and commercial success.
Learn more about our companion diagnostic
– Promoting faster, more collaborative analysis through the use of innovative, leading edge products and services to enable communication of richer efficacy signals faster and more cost-effectively.
Learn more about our digital pathology
We offer a quality management system that delivers high quality, dependable data for your study. All clinical laboratories across our regions ensure a globally harmonized SOP process that minimizes technical variability in your study. All of our expert pathologists, histotechnologists, clinical, and laboratory staff are trained in good documentation practices, with each AP lab containing on-site experts with >20 years’ experience.
Metrics are captured for turnaround time in each of our labs, with a goal of at least 98% achievement of turnaround time for each study. Our AP laboratories also participate in an accuracy-driven external quality assurance program (CAP Proficiency Testing) that supports our goal of achieving global harmonization, standardization and high quality results across the globe for every study.
Solutions can provide customized, global laboratory solutions specifically suited for the unique combinations of therapeutic indication and targeted mechanism-of-action driving modern oncology drug development.
||Our Testing Solutions
|Less Invasive Sampling
- Liquid biopsy: cell free nucleic acids and circulating tumor cells (CTCs)
- Mutation detection including Next Generation Sequencing
- Flow cytometry, immunoassays, proteomics
|Shift toward molecular methods
- Next generation sequencing (NGS) replacing FISH panels
- Gene expression panels replacing multiple IHCs
- Mutation detection at < 0.01%
- Single-cell analysis by flow cytometry/molecular platforms
- Detection of disease and early resistance
- Already established for many methods
- Expanding to genomics/NGS platforms
Experience predicting and assessing a patient’s response to checkpoint inhibitors is an integral function to immuno-oncology drug development. Once a tissue sample is received, central AP testing is performed and data can be mined for immuno-oncology characterizations, such as PD-L1 proteins or tumor-infiltrating lymphocytes. We then take those characterizations and apply them to drug studies, such as the creation of predictive biomarkers for patient selection.
Q2 Solutions has the breadth and depth of scientific experience and expertise across all major therapeutic areas, which help drug developers effectively gain a competitive advantage – helping ensure your success in clinical trials, regulatory approvals and new product launches.
We’re able to go a step further with our capability to validate, transfer, and employ new assays to meet today’s development opportunities. These abilities add significant value as we develop new assays for your trials. Learn more about our global AP capabilities.